Wells Fargo & Company Clene Inc. Transaction History

Wells Fargo & Company

$410 Billion
Q1 2024

A detailed history of Wells Fargo & Company transactions in Clene Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 733 shares of CLNN stock, worth $241. This represents 0.0% of its overall portfolio holdings.

Number of Shares

733

Previous 721 1.66%

Holding current value

$241

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.28 - $0.53 $3 - $6	12 Added 1.66%	733 $0
Q4 2023 Feb 09, 2024	BUY	$0.26 - $0.55 $9 - $20	37 Added 5.41%	721 $0
Q3 2023 Nov 13, 2023	BUY	$0.46 - $0.87 $205 - $388	447 Added 188.61%	684 $0
Q2 2023 Aug 15, 2023	BUY	$0.78 - $1.22 $17 - $28	23 Added 10.75%	237 $0
Q1 2023 May 12, 2023	BUY	$0.95 - $1.62 $2 - $4	3 Added 1.42%	214 $0

Q4 2022 Feb 13, 2023	BUY	$0.92 - $1.11 $70 - $85	77 Added 57.46%	211 $0
Q3 2022 Nov 14, 2022	SELL	$0.33 - $4.83 $3 - $48	-10 Reduced 6.94%	134 $0
Q2 2022 Aug 12, 2022	SELL	$2.1 - $4.12 $46,729 - $91,678	-22,252 Reduced 99.36%	144 $0
Q1 2022 May 16, 2022	BUY	$2.42 - $4.42 $26,019 - $47,523	10,752 Added 92.34%	22,396 $88,000
Q4 2021 Feb 14, 2022	SELL	$3.95 - $7.53 $34,254 - $65,300	-8,672 Reduced 42.69%	11,644 $48,000
Q3 2021 Nov 15, 2021	BUY	$6.83 - $13.58 $49,968 - $99,351	7,316 Added 56.28%	20,316 $138,000
Q2 2021 Aug 16, 2021	BUY	$6.98 - $13.33 $89,825 - $171,543	12,869 Added 9823.66%	13,000 $146,000
Q1 2021 May 13, 2021	BUY	$6.39 - $16.3 $837 - $2,135	131 New	131 $2,000

Others Institutions Holding CLNN

# of Institutions

Shares Held

7.44M

Call Options Held

48.1K

Put Options Held

160K

View Full List

About Clene Inc.

Ticker CLNN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,502,000
Market Cap $21M
Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...

More about CLNN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Clene Inc. Transaction History